AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
Phase 3
Recruiting
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- Drug: BGF MDI HFO 320/14.4/9.6μgDrug: BGF MDI HFA 320/14.4/9.6 μgDrug: Placebo MDI HFA
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT06075095
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
Phase 3
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT06067828
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT06068049
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Completed
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 628
- Registration Number
- NCT06056778
- Locations
- 🇷🇺
Research Site, Voronezh, Russian Federation
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
Phase 2
Completed
- Conditions
- COVID-19, SARS-CoV-2
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 116
- Registration Number
- NCT06057064
- Locations
- 🇷🇺
Research Site, St Petersburg, Russian Federation
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06053424
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Other: None (Observational study)
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT06046534
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
Phase 3
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 33
- Registration Number
- NCT06042049
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Phase 3
Active, not recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1454
- Registration Number
- NCT06040086
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06040099
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath